BASI News Alert Bioanalytical Systems (BASI) 2.16 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioanalytical Systems (BASI) 2.16 $BASI

Bioanalytical Systems to Release Fourth Quarter Fiscal 2014 Results on Wednesday December 17, 2014; Conference Call & Webcast Set For 11:00 a.m. EST
Business Wire - Fri Dec 12, 3:25PM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) will release financial results for the fourth quarter of fiscal 2014 ended September 30, 2014 at approximately 8:30 a.m. EST on Wednesday, December 17, 2014. BASi has scheduled a conference call at 11:00 a.m. EST that morning to discuss its results for the quarter. To participate in the call, dial 877-415-3179, participant passcode 30119869.
BASI: 2.16 (-0.02)

BASi's Culex(R) L Large Animal Sampling System Combines an Ideal Model with an Ideal Tool for Improved Drug Development Research
Business Wire - Tue Dec 02, 9:56AM CST
For nearly 15 years, the Culex(R) Automated Blood Sampling systems have allowed researchers to collect better data from non-stressed subjects. The cutting edge system saves time, saves money and saves lives by streamlining the drug discovery process and answering complicated questions at very early stages in research. Now, Bioanalytical Systems, Inc. (NASDAQ:BASI) has expanded that offering to a growing segment of drug discovery research utilizing swine as a research model.
BASI: 2.16 (-0.02)

Bioanalytical Systems (BASI) Upgraded From Sell to Hold
at The Street - Tue Nov 11, 8:08AM CST
Bioanalytical Systems (BASI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
BASI: 2.16 (-0.02)

Nasdaq stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UMPQ: 16.77 (-0.28), HBNK: 20.01 (-0.22), BRDR: 9.26 (+0.19), SAPE: 24.83 (+0.01), TAIT: 1.17 (+0.11), BASI: 2.16 (-0.02), GERN: 3.24 (+0.01), NYMX: 0.33 (-0.05), MTEX: 28.10 (-1.00), CKEC: 26.46 (-0.09), ALQA: 4.01 (-0.14)

BASi Names Connie Dougherty Vice President Business Development
Business Wire - Tue Sep 16, 2:02PM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced the appointment of Connie Dougherty as Vice President of Business Development reporting to BASi President and Chief Executive Officer Jacqueline Lemke. She will provide leadership to drive BASi's growth initiatives and efforts to expand the Company's footprint.
BASI: 2.16 (-0.02)

Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART D: ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
A: 39.72 (-0.90), OSIR: 12.92 (-0.04), ILMN: 184.30 (-2.53), LMNX: 17.94 (-0.29), AFFX: 8.94 (-0.36), QGEN: 22.95 (-0.29), BCOR: 13.16 (-0.06), ACCL: 12.51 (+0.03), ABT: 43.69 (-0.77), INCY: 74.65 (-1.27), BMY: 58.75 (-0.93), WAT: 111.56 (-1.80), ISIS: 62.32 (+0.45), SIAL: 136.00 (-0.09), BASI: 2.16 (-0.02), MRK: 57.72 (-1.62), CGEN: 8.27 (+0.14), CRL: 62.66 (-0.32), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)

CORRECTING and REPLACING BASi Reports Third Quarter Net Income of $.03 Per Share
Business Wire - Thu Aug 14, 8:12AM CDT
In the "Earnings Conference Call" paragraph of the release, the second sentence should read: To participate in the call, dial 866.515.2912, passcode #12839680 at least five minutes before the start of the call.
BASI: 2.16 (-0.02)

BASi Reports Third Quarter Net Income of $.03 Per Share
Business Wire - Thu Aug 14, 7:00AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the third quarter and first nine months of fiscal 2014.
BASI: 2.16 (-0.02)

Bioanalytical Systems to Release Third Quarter Fiscal 2014 Results on Thursday August 14, 2014; Conference Call & Webcast Set for 11:00 a.m. EDT
GlobeNewswire - Wed Aug 06, 12:00PM CDT
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the third quarter of fiscal 2014 ended June 30, 2014 at approximately 8:30 a.m. EDT on Thursday, August 14, 2014. BASi has scheduled a conference call at 11:00 a.m. EDT that morning to discuss its results for the quarter. To participate in the call, dial 866.555.2912, passcode #12839680.
BASI: 2.16 (-0.02)

BASi Names Jeffrey Potrzebowski CFO and James Bourdage VP Bioanalytical Operations
Business Wire - Thu Jun 12, 7:01AM CDT
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced the appointment of Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.
BASI: 2.16 (-0.02)

BASi Reports First Quarter Results
Business Wire - Thu Feb 13, 7:00AM CST
Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the first quarter of fiscal 2014.
PRU: 86.66 (-3.13), BASI: 2.16 (-0.02)

Bioanalytical Systems to Release First Quarter Fiscal 2014 Results on Thursday, February 13, 2014; Conference Call & Webcast Set for 11:00 a.m. EST
GlobeNewswire - Wed Feb 05, 7:00AM CST
Bioanalytical Systems, Inc. (Nasdaq:BASI) will release financial results for the first quarter of fiscal 2014 ended December 31, 2013 at approximately 8:30 a.m. EST on Thursday, February 13, 2014. BASi has scheduled a conference call at 11:00 a.m. EST that morning to discuss its results for the quarter. To participate in the call, dial 800 299.9630, passcode #66359984.
BASI: 2.16 (-0.02), PHM.VN: 0.700 (+0.020)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading